Immunogenicity against hepatitis C virus with mesenchymal stem cells of inbreed BALB/c mice sub cloned with HCVcp protein gene

Masoudi, Mahmood Reza; Rafati, Alireza

doi:10.1016/j.trim.2022.101651

Cited by 2 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is little information available on obtaining and studying genetically modified MSCs as preventive and therapeutic vaccines against viral diseases. A number of studies have demonstrated the potential of mouse mMSCs as innovative vaccines to enhance the immune responses against HIV [ 37 ], hepatitis C [ 24 , 38 ], human papillomavirus [ 39 ], and herpes simplex virus type 1 [ 40 ]. However, the positive results obtained with mouse MSCs, when switching to experiments with human MSCs, are not always confirmed, which may be caused by differences both in the properties of the cells themselves and in the immune reactions induced by them [ 25 , 26 , 41 ].…”

Section: Discussionmentioning

confidence: 99%

Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene

Масалова

Леснова

Kalsin

et al. 2023

Biology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is one of the basic culprits behind chronic liver disease, which may result in cirrhosis and hepatocarcinoma. In spite of the extensive research conducted, a vaccine against HCV has not been yet created. We have obtained human mesenchymal stem cells (hMSCs) and used them for expressing the HCV NS5A protein as a model vaccination platform. Sixteen hMSC lines of a different origin were transfected with the pcNS5A-GFP plasmid to obtain genetically modified MSCs (mMSCs). The highest efficiency was obtained by the transfection of dental pulp MSCs. C57BL/6 mice were immunized intravenously with mMSCs, and the immune response was compared with the response to the pcNS5A-GFP plasmid, which was injected intramuscularly. It was shown that the antigen-specific lymphocyte proliferation and the number of IFN-γ-synthesizing cells were two to three times higher after the mMSC immunization compared to the DNA immunization. In addition, mMSCs induced more CD4+ memory T cells and an increase in the CD4+/CD8+ ratio. The results suggest that the immunostimulatory effect of mMSCs is associated with the switch of MSCs to the pro-inflammatory phenotype and a decrease in the proportion of myeloid derived suppressor cells. Thus, the possibility of using human mMSCs for the creation of a vaccine against HCV has been shown for the first time.

show abstract

Section: Discussionmentioning

confidence: 99%

Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene

Масалова

Леснова

Kalsin

et al. 2023

Biology

View full text Add to dashboard Cite

show abstract

“…The immunized mice demonstrated a superior humoral immunogenic response and produced core-specific antibodies. The transfected MCS-treated mice also exhibited a significant increase in splenocyte proliferation compared to the control group l [43].…”

Section: Core Proteinsmentioning

confidence: 92%

Future Prospects, Approaches, and the Government’s Role in the Development of a Hepatitis C Virus Vaccine

Tabll,

Sohrab,

Ali

et al. 2023

Pathogens

View full text Add to dashboard Cite

Developing a safe and effective vaccine against the hepatitis C virus (HCV) remains a top priority for global health. Despite recent advances in antiviral therapies, the high cost and limited accessibility of these treatments impede their widespread application, particularly in resource-limited settings. Therefore, the development of the HCV vaccine remains a necessity. This review article analyzes the current technologies, future prospects, strategies, HCV genomic targets, and the governmental role in HCV vaccine development. We discuss the current epidemiological landscape of HCV infection and the potential of HCV structural and non-structural protein antigens as vaccine targets. In addition, the involvement of government agencies and policymakers in supporting and facilitating the development of HCV vaccines is emphasized. We explore how vaccine development regulatory channels and frameworks affect research goals, funding, and public health policy. The significance of international and public-private partnerships in accelerating the development of an HCV vaccine is examined. Finally, the future directions for developing an HCV vaccine are discussed. In conclusion, the review highlights the urgent need for a preventive vaccine to fight the global HCV disease and the significance of collaborative efforts between scientists, politicians, and public health organizations to reach this important public health goal.

show abstract

Immunogenicity against hepatitis C virus with mesenchymal stem cells of inbreed BALB/c mice sub cloned with HCVcp protein gene

Cited by 2 publications

References 18 publications

Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene

Human Mesenchymal Stem Cells Modified with the NS5A Gene of Hepatitis C Virus Induce a Cellular Immune Response Exceeding the Response to DNA Immunization with This Gene

Future Prospects, Approaches, and the Government’s Role in the Development of a Hepatitis C Virus Vaccine

Contact Info

Product

Resources

About